164 related articles for article (PubMed ID: 27258968)
21. Cost-effectiveness of proton therapy in treating base of skull chordoma.
Austin AM; Douglass MJJ; Nguyen GT; Dalfsen R; Le H; Gorayski P; Tee H; Penniment M; Penfold SN
Australas Phys Eng Sci Med; 2019 Dec; 42(4):1091-1098. PubMed ID: 31646441
[TBL] [Abstract][Full Text] [Related]
22. Proton beam therapy for the treatment of prostate cancer.
Pugh TJ; Lee AK
Cancer J; 2014; 20(6):415-20. PubMed ID: 25415688
[TBL] [Abstract][Full Text] [Related]
23. High-dose proton beam therapy versus conventional fractionated radiation therapy for newly diagnosed glioblastoma: a propensity score matching analysis.
Matsuda M; Mizumoto M; Kohzuki H; Sugii N; Sakurai H; Ishikawa E
Radiat Oncol; 2023 Feb; 18(1):38. PubMed ID: 36823671
[TBL] [Abstract][Full Text] [Related]
24. [Proton therapy in soft tissue and bone sarcomas].
Thariat J; Tessonnier T; Bonvalot S; Lerouge D; Mammar H; Bolle S; Claren A; Duffaud F; Alapetite C; Vogin G
Bull Cancer; 2018 Sep; 105(9):830-838. PubMed ID: 30126610
[TBL] [Abstract][Full Text] [Related]
25. Secondary neutron doses in a compact proton therapy system.
Stichelbaut F; Closset M; Jongen Y
Radiat Prot Dosimetry; 2014 Oct; 161(1-4):368-72. PubMed ID: 24591728
[TBL] [Abstract][Full Text] [Related]
26. Proton therapy of iris melanoma with 50 CGE : Influence of target volume on clinical outcome.
Riechardt AI; Karle B; Cordini D; Heufelder J; Budach V; Joussen AM; Gollrad J
Strahlenther Onkol; 2017 Nov; 193(11):943-950. PubMed ID: 28631017
[TBL] [Abstract][Full Text] [Related]
27. Dosimetric comparison between VMAT with different dose calculation algorithms and protons for soft-tissue sarcoma radiotherapy.
Fogliata A; Scorsetti M; Navarria P; Catalano M; Clivio A; Cozzi L; Lobefalo F; Nicolini G; Palumbo V; Pellegrini C; Reggiori G; Roggio A; Vanetti E; Alongi F; Pentimalli S; Mancosu P
Acta Oncol; 2013 Apr; 52(3):545-52. PubMed ID: 22671576
[TBL] [Abstract][Full Text] [Related]
28. Radiation-Induced Moyamoya Syndrome after Proton Beam Therapy in the Pediatric Patient: A Case Series.
Reynolds MR; Haydon DH; Caird J; Leonard JR
Pediatr Neurosurg; 2016; 51(6):297-301. PubMed ID: 27193755
[TBL] [Abstract][Full Text] [Related]
29. Proton beam radiation therapy for prostate cancer-is the hype (and the cost) justified?
Gray PJ; Efstathiou JA
Curr Urol Rep; 2013 Jun; 14(3):199-208. PubMed ID: 23546839
[TBL] [Abstract][Full Text] [Related]
30. Long-term cosmetic outcomes and toxicities of proton beam therapy compared with photon-based 3-dimensional conformal accelerated partial-breast irradiation: a phase 1 trial.
Galland-Girodet S; Pashtan I; MacDonald SM; Ancukiewicz M; Hirsch AE; Kachnic LA; Specht M; Gadd M; Smith BL; Powell SN; Recht A; Taghian AG
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):493-500. PubMed ID: 24880212
[TBL] [Abstract][Full Text] [Related]
31. Is proton-beam therapy better than intensity-modulated radiation therapy for prostate cancer?
Kagan AR; Yeh J; Schulz RJ
Am J Clin Oncol; 2014 Dec; 37(6):525-7. PubMed ID: 24577165
[No Abstract] [Full Text] [Related]
32. Proton beam therapy for hepatocellular carcinoma.
Yeung RH; Chapman TR; Bowen SR; Apisarnthanarax S
Expert Rev Anticancer Ther; 2017 Oct; 17(10):911-924. PubMed ID: 28825506
[TBL] [Abstract][Full Text] [Related]
33. Spot scanning proton therapy for malignancies of the base of skull: treatment planning, acute toxicities, and preliminary clinical outcomes.
Grosshans DR; Zhu XR; Melancon A; Allen PK; Poenisch F; Palmer M; McAleer MF; McGovern SL; Gillin M; DeMonte F; Chang EL; Brown PD; Mahajan A
Int J Radiat Oncol Biol Phys; 2014 Nov; 90(3):540-6. PubMed ID: 25304948
[TBL] [Abstract][Full Text] [Related]
34. Differential dosimetric benefit of proton beam therapy over intensity modulated radiotherapy for a variety of targets in patients with intracranial germ cell tumors.
Park J; Park Y; Lee SU; Kim T; Choi YK; Kim JY
Radiat Oncol; 2015 Jun; 10():135. PubMed ID: 26112360
[TBL] [Abstract][Full Text] [Related]
35. Promise and pitfalls of heavy-particle therapy.
Mitin T; Zietman AL
J Clin Oncol; 2014 Sep; 32(26):2855-63. PubMed ID: 25113772
[TBL] [Abstract][Full Text] [Related]
36. Proton Therapy for Head and Neck Cancer.
Kim JK; Leeman JE; Riaz N; McBride S; Tsai CJ; Lee NY
Curr Treat Options Oncol; 2018 May; 19(6):28. PubMed ID: 29744681
[TBL] [Abstract][Full Text] [Related]
37. Proton therapy posterior beam approach with pencil beam scanning for esophageal cancer : Clinical outcome, dosimetry, and feasibility.
Zeng YC; Vyas S; Dang Q; Schultz L; Bowen SR; Shankaran V; Farjah F; Oelschlager BK; Apisarnthanarax S; Zeng J
Strahlenther Onkol; 2016 Dec; 192(12):913-921. PubMed ID: 27596221
[TBL] [Abstract][Full Text] [Related]
38. Assessing the uncertainty in a normal tissue complication probability difference (∆NTCP): radiation-induced liver disease (RILD) in liver tumour patients treated with proton vs X-ray therapy.
Kobashi K; Prayongrat A; Kimoto T; Toramatsu C; Dekura Y; Katoh N; Shimizu S; Ito YM; Shirato H
J Radiat Res; 2018 Mar; 59(suppl_1):i50-i57. PubMed ID: 29538699
[TBL] [Abstract][Full Text] [Related]
39. Comparison of adverse effects of proton and X-ray chemoradiotherapy for esophageal cancer using an adaptive dose-volume histogram analysis.
Makishima H; Ishikawa H; Terunuma T; Hashimoto T; Yamanashi K; Sekiguchi T; Mizumoto M; Okumura T; Sakae T; Sakurai H
J Radiat Res; 2015 May; 56(3):568-76. PubMed ID: 25755255
[TBL] [Abstract][Full Text] [Related]
40. Proton therapy for pediatric cancer: are we ready for prime time?
Chapman TR; Ermoian RP
Future Oncol; 2017 Jan; 13(1):5-8. PubMed ID: 27905257
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
